News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmatrix's PUR0200 Demonstrated Encouraging Results In Phase 1B Clinical Study In COPD Patients


5/5/2014 9:52:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate, PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule formulation from the company's novel iSPERSEā„¢ inhaled dry powder technology. The Phase 1B clinical trial compared the pharmacokinetic/pharmacodynamic profile of single doses of PUR0200 to an active comparator or placebo in patients with moderate to severe COPD.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Pulmatrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES